Kyverna Therapeutics, Inc. KYTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s total equity?
- Kyverna Therapeutics, Inc. (KYTX) reported total equity of $195.58M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total equity changed year-over-year?
- Kyverna Therapeutics, Inc.'s total equity decreased by 12.7% year-over-year, from $224.01M to $195.58M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total equity?
- Over 3 years (2022 to 2025), Kyverna Therapeutics, Inc.'s total equity has grown at a 46.4% compound annual growth rate (CAGR), from -$74M to $232.28M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.